Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of “Hold” from Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average recommendation of “Hold” by the seventeen brokerages that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $45.50.

Several research analysts have recently weighed in on the stock. Barclays began coverage on shares of Hims & Hers Health in a research report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. KeyCorp began coverage on Hims & Hers Health in a report on Tuesday, October 21st. They set a “sector weight” rating on the stock. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $33.06 on Friday. The stock’s fifty day simple moving average is $39.03 and its 200 day simple moving average is $47.39. The stock has a market capitalization of $7.53 billion, a price-to-earnings ratio of 61.22, a PEG ratio of 6.74 and a beta of 2.41. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67. Hims & Hers Health has a 52-week low of $23.97 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 EPS. As a group, sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its Board of Directors has authorized a share repurchase plan on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This trade represents a 53.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $367,870.91. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 143,198 shares of company stock valued at $5,841,685 in the last 90 days. Corporate insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Quent Capital LLC purchased a new stake in shares of Hims & Hers Health during the 3rd quarter worth about $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health during the third quarter valued at approximately $28,000. Virtus Advisers LLC bought a new position in Hims & Hers Health during the second quarter valued at approximately $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $29,000. Finally, Bessemer Group Inc. grew its position in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.